The future of women's contraception: Stakes and modalities

Annals of the New York Academy of Sciences

Volumn 1205, Issue , 2010, Pages 230-239

  Hugon Rodin, Justine ^a   Chabbert Buffet, Nathalie ^b,c   Bouchard, Philippe ^a,c  

^a HÔPITAL SAINT ANTOINE   (France)

^b HÔPITAL TENON   (France)

^c SORBONNE UNIVERSITÉ   (France)

Author keywords

antiprogesterones; emergency contraception; estradiol containing pill; SPRM

Indexed keywords

'JASMINE'; CHORIONIC GONADOTROPIN; CYPROTERONE ACETATE; DIENILLE; DIENOGEST PLUS ESTRADIOL VALERATE; DIENOGEST PLUS ETHINYLESTRADIOL; DROSPIRENONE; DROSPIRENONE PLUS ETHINYLESTRADIOL; ELCOMETRINE; ELLA ONE; ESTETROL; ESTRADIOL; ESTRADIOL CYPIONATE PLUS MEDROXYPROGESTERONE ACETATE; ESTRADIOL VALERATE PLUS NORETHISTERONE ENANTATE; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS ETONOGESTREL; ETHINYLESTRADIOL PLUS LEVONORGESTREL; ETHINYLESTRADIOL PLUS NORELGESTROMIN; ETONOGESTREL; FEMILIS; FEMILIS SLIM; FIBROPLANT; FOLLITROPIN; GESTAGEN; GONADORELIN; JASMINELLE; KLAIRA; LEVONORGESTREL; LOESTRIN 24 FE; MEDROXYPROGESTERONE ACETATE; MELOXICAM; MESTRANOL; MIFEPRISTONE; NOMEGESTROL ACETATE; NORETYNODREL; PROGESTERONE RECEPTOR MODULATOR; QLAIRA; QUASENSE; ULIPRISNIL ACETATE; ULIPRISTAL; ULIPRISTAL ACETATE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VA 2914; YAZ FLEX; CONTRACEPTIVE AGENT;

ABDOMINAL PAIN; ABORTION; BIRTH CONTROL; BONE MASS; BREAKTHROUGH BLEEDING; BREAST CANCER; CANCER RISK; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONDOM; CONFERENCE PAPER; CONTRACEPTION; DEEP VEIN THROMBOSIS; DRUG ABSORPTION; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG POTENTIATION; EMERGENCY CONTRACEPTION; FRANCE; GENOMICS; HEART INFARCTION; HUMAN; IMMUNOLOGY; INTRAUTERINE CONTRACEPTIVE DEVICE; NAUSEA; NIGERIA; NONHUMAN; ORAL CONTRACEPTION; PATIENT COMPLIANCE; PROTEOMICS; SEXUAL BEHAVIOR; SEXUALLY TRANSMITTED DISEASE; UNITED STATES; UNPLANNED PREGNANCY; UNSPECIFIED SIDE EFFECT; VASCULAR DISEASE; VENOUS THROMBOEMBOLISM; EVALUATION STUDY; FEMALE; INDUCED ABORTION; PREGNANCY; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME; UNWANTED PREGNANCY;

ABORTION, INDUCED; CONTRACEPTION; CONTRACEPTIVE AGENTS, FEMALE; ETHINYL ESTRADIOL; FEMALE; HUMANS; INTRAUTERINE DEVICES; PREGNANCY; PREGNANCY, UNWANTED; TREATMENT OUTCOME;

EID: 77957084554     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2010.05688.x     Document Type: Conference Paper

References (40)

1. INED. 2003. United Nations. World Contraceptive Use. www.ined.fr .
2. Guttmacher, I. 2009. Facts on induced abortion worldwide. www.guttmacher.org .
3. Guttmacher, I. 2008. Facts on contraceptive use. www.guttmacher.org .
4. Guttmacher, I. 2006. Facts on unwanted pregnancy and induced abortion in Nigeria. www.guttmacher.org .
5. Bajos, N. et al. 2003. Contraception: from accessibility to efficiency. Hum. Reprod. 18: 994-999.
6. Moreau, C. et al. 2007. Contraceptive failure rates in France: results from a population-based survey. Hum. Reprod. 22: 2422-2427.
7. CollaborativeGroup onHormonal Factors in Breast Cancer. 1996. Lancet 347: 1713-1727.
8. Hannaford, P.C. et al. 2007. Cancer risk among users of oral contraceptives: cohort data from the Royal College of General Practitioners oral contraception study. BMJ 335: 651-658.
9. Dinger, J.C., L.A. Heinemann & D. Kuhl-Habich. 2007. The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation. Contraception 75: 344-354.
10. Van Hylckama Vlieg, A. et al. 2009. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study. BMJ 339: 2921-2928.
11. Lidegaard, O. et al. 2009. Hormonal contraception and risk of venous thromboembolism: national follow-up study.BMJ 339: 2890-2897.
12. -2008. Hormonal contraception: recent advances and controversies. Fertil. Steril. 90: S103-S113.
13. Pikkarainen, E. et al. 2008. Estrogen-progestin contraceptive use during adolescence prevents bone mass acquisition: a 4-year follow-up study. Contraception 78: 226-231.
14. Tremollieres, F. 2005. Effect of hormonal contraception on bone mineral density. Gynecol. Obstet. Fertil. 33: 520-525.
15. Hannaford, P.C. et al. 2010. Mortality among contraceptive pill users: cohort evidence from Royal College of General Practitioners Oral Contraception Study. BMJ 340: c927.
16. Rowlands, S. 2009. New technologies in contraception. BJOG 116: 230-239.
17. Jain, J. et al. 2004. Contraceptive efficacy and safety of DMPA-SC. Contraception 70: 269-275.
18. Sivin, I. et al. 2005. Contraceptive vaginal rings releasing Nestorone and ethinylestradiol: a 1-year dose-finding trial. Contraception 71: 122-129.
19. Meirik, O. 2002. Implantable contraceptives for women. Contraception 65: 1-2.
20. Nakajima, S.T., D.F. Archer & H. Ellman. 2007. Efficacy and safety of a new 24-day oral contraceptive regimen of norethindrone acetate 1 mg/ethinyl estradiol 20 micro g (Loestrin 24 Fe). Contraception 75: 16-22.
21. Mutter, G.L. et al. 2008. The spectrum of endometrial pathology induced by progesterone receptor modulators. Mod. Pathol. 21: 591-598.
22. Pei, K. et al. 2007.Weekly contraception with mifepristone. Contraception 75: 40-44.
23. Cheng, L. et al. 2000. Once a month administration of mifepristone improves bleeding patterns in women using subdermal contraceptive implants releasing levonorgestrel. Hum. Reprod. 15: 1969-1972.
24. Chabbert-Buffet, N.,A. Pintiaux-Kairis&P. Bouchard. 2007. Effects of the progesterone receptor modulator VA2914 in a continuous lowdose on the hypothalamic-pituitary-ovarian axis and endometriumin normalwomen: a prospective, randomized, placebo-controlled trial. J. Clin. Endocrinol.Metab. 92: 3582-3589.
25. Creinin, M.D. et al. 2006. Progesterone receptor modulator for emergency contraception: a randomized controlled trial. Obstet. Gynecol. 108: 1089-1097.
26. Fine, P. et al. 2010. Ulipristal acetate taken 48-120 hours after intercourse for emergency contraception. Obstet. Gynecol. 115: 257-263.
27. Glasier, A.F. et al. 2010. Ulipristal acetate versus levonorgestrel for emergency contraception: a randomized non-inferiority trial and meta-analysis. Lancet 375: 555-562.
28. Croxatto, H.B. et al. 2006. Feasibility study of Nestoroneethinylestradiol vaginal contraceptive ring for emergency contraception. Contraception 73: 46-52.
29. Cutler, B. & J. Justman. 2008. Vaginal microbicides and the prevention of HIV transmission. Lancet Infect. Dis. 8: 685-697.
30. Delves, P.J. 2004. How far from a hormone-based contraceptive vaccine? J. Reprod. Immunol. 62: 69-78.
31. Naz, R.K. 2009. Status of contraceptive vaccines. Am. J. Reprod. Immunol. 61: 11-18.
32. Aitken, R.J. et al. 2008. As the world grows: contraception in the 21st century. J. Clin. Invest. 118: 1330-1343.
33. Schultz, N., F.K.Hamra&D.L.Garbers. 2003.Amultitude of genes expressed solely in meiotic or postmeiotic spermatogenic cells offers amyriad of contraceptive targets. Proc.Natl. Acad. Sci. USA 100: 12201-12206.
34. Spruck, C.H. et al. 2003. Requirement of Cks2 for the first metaphase/anaphase transition of mammalian meiosis. Science 300: 647-650.
35. Fan, H.Y. et al. 2009. MAPK3/1 (ERK1/2) in ovarian granulose cells are essential for female fertility. Science 324: 938-941.
36. Wu, X. et al. 2003. Zygote arrest 1 (Zar1) is an evolutionarily conserved gene expressed in vertebrate ovaries. Biol. Reprod. 69: 861-867.
37. Jensen, J.T. et al. 2008. The phosphodiesterase 3 inhibitor ORG 9935 inhibits oocyte maturation in the naturally selected dominant follicle in rhesus macaques. Contraception 77: 303-307.
38. Alfieri, J.A. et al. 2003. Infertility in female mice with an oocyte-specific knockout of GPI-anchored proteins. J. Cell Sci. 116: 2149-2155.
39. White, C.A. et al. 2007. Blocking LIF action in the uterus by using a PEGylated antagonist prevents implantation: a nonhormonal contraceptive strategy. Proc. Natl. Acad. Sci. USA 104: 19357-19362.
40. Sharkey, A.M. et al. 2005. Novel antiangiogenic agents for use in contraception. Contraception 71: 263-271.